37results about How to "High relaxation efficiency" patented technology

The invention provides a paramagnetic metal complex functionalized fluorogold nano-cluster magnetic resonance and fluorescence imaging contrast agent. The invention relates to the field of magnetic resonance imaging and fluorescence imaging contrast agents. With the contrast agent provided by the invention, problems of existing contrast agents of low relaxation efficiency, high toxicity, low tissue organ selectivity and fast in-vivo metabolism can be solved. According to the invention, ethylenediaminetetraacetic acid (EDTA) or diethylene triaminepentaacetic acid (DTPA) are connected to folic-acid-modified bovine serum albumin fluorogold nano-clusters through amide bonds; and EDTA or DTPA is respectively coordinated with paramagnetic metal ions, such that the complex is obtained. With the contrast agent provided by the invention, the relaxation efficiency can reach 23.7mM<-1>*s<-1>. The contrast agent has an advantage of low toxicity. According to the invention, high spatial resolution of magnetic resonance imaging and high sensitivity of fluorescence imaging are combined. Therefore, the contrast agent provided by the invention can be used in magnetic resonance imaging and fluorescence imaging.

The invention relates to a magnetic resonance image contrast agent which uses arabinogalactan as carrier, wherein its production comprises that: using ethylenediamine tetra acetic acid, diethylene triamine pentacetic acid N-butanimide active ester, ethylenediamine tetra acetic acid, or the anhydrides of diethylene triamine pentacetic, via one short connecting arm to react with amination arabinogalactan; forming amido bond to connect ethylenediamine tetra acetic acid or diethylene triamine pentacetic acid to the arabinogalactan, to match magnetic metal ion as manganese, iron or lanthanide rare-earth element, to obtain complex. The invention has significant liver selectivity and low cute toxin. And the inventive contrast agent can be used in magnetic resonance diagnosis, X-ray CT or Y-flash imaging diagnosis.

The invention provides a paramagnetic metal complex and a synthetic method and application thereof. The paramagnetic metal complex is an arabinogalactan-modified 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacethyl paramagnetic metal complex. A magnetic resonance imaging contrast agent prepared from the paramagnetic metal complex has high stability, water solubility and relaxation rate and is targeted to liver and kidney, so that targeted imaging is realized, and the imaging contrast and definition are improved. The paramagnetic metal complex has a good effect on raising the early diagnosis levels of diseases of liver and kidney organs, is about 2 times the relaxation rate of dotarem, has very long targeted radiography imaging time, can be easily prepared into a solution with required concentration for intravenous injection, is suitable for sterilizing and disinfecting with a hot pressing method, can be selectively identified by an asialoglycoprotein receptor on a liver parenchyma surface, and has high selectivity on livers of human beings or other mammals.

The invention discloses a similar EDTA ligand namely 2,2',2'',2'''-((3-(3,4-dihydroxyphenyl) propane-1,2diyl) ethylene diamine tetraacetic containing O-phenolic hydroxyl, a non-gadolinium paramagnetic metal coordination compound namely a magnetic resonance contrast agent based on the ligand, a non-gadolinium metal agglomeration body namely a magnetic resonance contrast agent, a preparation method of the similar EDTA ligand, a preparation method of the non-gadolinium paramagnetic metal coordination compound namely the magnetic resonance contrast agent, and a preparation method of the non-gadolinium metal agglomeration body namely the magnetic resonance contrast agent. The 2,2',2'',2'''-((3-(3,4-dihydroxyphenyl) propane-1,2diyl) ethylene diamine tetraacetic is prepared for the first time, and the ligand combines the advantages of two structures of the O-phenolic hydroxyl and the EDTA, so that the non-gadolinium magnetic resonance contrast agent based on the ligand has high relaxation efficiency, good water solubility and good structure stability. Compared with a Gd type contrast agent used clinically, the non-gadolinium magnetic resonance contrast agent based on the ligand has the advantages that an order metal agglomeration body namely the contrast agent is self-assembled through coordination, the MRI imaging effects are better, more details can be displayed, and accurate analysis basis is provided for diagnosing multiple diseases.

The invention relates to the technical field of preparing a contrast agent by utilizing a hyperbranched polymer. A preparing method of the hyperbranched polymer includes reacting a lysine salt and caustic alkali in a mole ratio of 100:80-90 at 140-160 DEG C for 40-50 h in a protective atmosphere; mixing a hyperbranched polylysine skeleton and diethylenetriaminepentaacetic acid according to a mass ratio of at least 1:5 in water; reacting the mixture at room temperature for 6-8 h; mixing the first hyperbranched polylysine molecule and a gadolinium compound in water; reacting the mixture at 37-42 DEG C for 6-12 h, with the mass ratio of the first hyperbranched polylysine molecule to the gadolinium compound being 1:1-1:2; and mixing and reacting the second hyperbranched polylysine molecule and folic acid in a carbonate the pH value of which is 8-10 for 5-12 h. The hyperbranched polylysine contrast agent has good biocompatibility, low toxicity and a high relaxation rate and can be metabolized in vivo.

The invention relates to a magnetic resonance contrast agent using a human endogenous protein as a chelating agent and preparation thereof. The contrast agent comprises the chelating agent and paramagnetic metal ions coordinated with the chelating agent, the chelating agent is the human endogenous protein, and the human endogenous protein includes aspartic acid and glutamic acid; during the preparation, firstly the human endogenous protein is added to water, the human endogenous protein is dissolved by stirring, and then trisodium citrate dihydrate is added and stirred evenly to obtain a mixedsolution; paramagnetic metal salt is added and stirred to coordinate the paramagnetic metal ions with the chelating agent so as to obtain a reaction solution, finally the pH of the reaction solutionis adjusted to 5.0-7.4, and then the reaction solution is separated and dried. Compared with the prior art, the contrast agent is formed by the direct chelation of the human endogenous protein and theparamagnetic metal ions, and traditional micro-molecule chelating agents are not needed; the contrast agent has simple synthesis process, mild reaction conditions and good environmental compatibility, reduces energy consumption, and is easy in mass production.

An MRI contrast medium using glycyrrhizic acid as its carrier is prepared through reaction between the mono-N-hydroxy succinimide (and monocyclic acid anhydride) of EDTA (or biethyltriamino pentacetate) and aminated glycyrrhizic acid, and coordinating with paramagnetic metal ions to obtain a match. It has high elaxation efficiency and selectivity to liver, and lower acute toxin. It can also be used for X-ray CT and gamma-ray flash imaging technique.

The invention discloses a tumor diagnosis and treatment integrated nano material based on manganese base, a preparation method and application. According to the preparation method, albumin, hypericinand manganese chloride are added into an aqueous medium, and the product is self-assembled to form the tumor diagnosis and treatment integrated nano material. An efficient manganese-base nanoscale macromolecular contrast agent is prepared through self-assembly and has the advantages of being high in relaxation efficiency, long in in-vivo circulation time, rapid in kidney removal, high in targetingproperty and biocompatibility, small in toxic and side effect and the like. The nano material prepared by the invention has relatively high photodynamic conversion efficiency at 595nm, can be used asa photosensitizer to be applied to photodynamic therapy. In addition, the position and size of a tumor and the enrichment condition of the phototherapeutic agent in tumor tissue are monitored by means of a magnetic resonance technology, the nano material is used for evaluating the treatment effect, and magnetic resonance imaging-mediated photodynamic therapy diagnosis and treatment integration isachieved.

The invention discloses a 2-nuclear magnetic resonance imaging contrast agent taking 2, 3-biquinoxaline as a connecting body and a preparation method of the 2-nuclear magnetic resonance imaging contrast agent, relating to the technical field of magnetic resonance imaging contrast agents. The 2-nuclear magnetic resonance imaging contrast agent taking the 2, 3-biquinoxaline as the connecting body solves the problems that the relaxation efficiency is low and the thermodynamic stability is poor as the contrast agent adopts a flexible chain to connect a group in the prior art. According to the contrast agent, two DO3A groups are in covalent connection on the rigid-connection group 2, 3-biquinoxaline, and then the rigid-connection group 2, 3-biquinoxaline is chelated with paramagnetism metal ion Gd3<+> to obtain the 2-nuclear magnetic resonance imaging contrast agent. The invention also provides the preparation method of the 2-nuclear magnetic resonance imaging contrast agent taking the 2, 3-biquinoxaline as the connecting body. The relaxation efficiency of the contrast agent (Gd-Do3A)-BMQX can achieve 6.2mM<-1>s<-1>, and the 2-nuclear magnetic resonance imaging contrast agent has good stability and is low in toxicity.

The invention relates to a water-soluble magnetic resonance imaging contrast agent containing a nitroimidazole group and a preparation method of the contrast agent, belonging to the technical fields of medicine and chemistry. The contrast agent is prepared by the following steps: carrying out an esterification reaction between an active derivative of polyaminopolycarboxylate and a compound containing the nitroimidazole group under the effect of microwave to obtain a novel organic ligand containing the nitroimidazole group; and chelating the ligand with paramagnetic metal ions to obtain a corresponding paramagnetic metal chelate contrast agent. The contrast agent disclosed by the invention is high in relaxation efficiency and good in water solubility, and especially has a kidney targeting property; and the contrast agent is applicable to the magnetic resonance imaging technology of various tissues or organs of human bodies or other mammals.

The invention provides a paramagnetism metal complex magnetic resonance imaging contrast agent containing asparaginic acid-glucan and a preparation method of the contrast agent, to solve the problem that in the prior art the contrast agent is low in relaxation rate. According to the contrast agent, the glucan is used as a carrier; asparaginic acid is connected with 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and is further subjected to coordination with the paramagnetism metal ions in a mole ratio of 1:1 so as to obtain the complex. According to the preparation method of the paramagnetism metal complex magnetic resonance imaging contrast agent containing the asparaginic acid-glucan, the contrast agent with relatively higher relaxation efficiency is obtained by controlling the dosage ratio of reaction raw materials, the pH value of solution, the reaction temperature and the reaction time. The contrast agent can be used for magnetic resonance imaging; after the contrast agent imaging is accomplished, the asparaginic acid carried in the contrast agent has protection function on hearts, and therefore the contrast agent is an imaging contrast agent with double functions.

The invention provides a magnetic resonance contrast agent as well as a preparation method and application thereof, and relates to the field of magnetic resonance contrast agents. The magnetic resonance contrast agent disclosed by the invention is prepared from a compound with structural characteristics of a formula I shown in the description. The magnetic resonance contrast agent disclosed by the invention can also be a compound with structural characteristics shown as a formula II or pharmaceutically acceptable salt thereof, M1 is a +2 ion of paramagnetic metal Mn, Fe, Eu or Dy, or a +3 ion of Mn, Fe, Eu or Dy; M2 is Na < + >, K < + > or meglumine cation; when M1 is a +2 valence ion, a is equal to 2; and when M1 is a + 3 valence ion, a is equal to 3. The magnetic resonance contrast agent has the characteristics of good water solubility, high relaxation efficiency, low toxic and side effects and the like.